Scleroderma Diagnostics and Therapeutics Market Report 2026

The scleroderma diagnostics and therapeutics market size has grown strongly in recent years. It will grow from $2.94 billion in 2025 to $3.19 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to limited awareness of scleroderma, lack of targeted therapies, conventional diagnostic methods, low early diagnosis rates, regional healthcare disparities.

The scleroderma diagnostics and therapeutics market size is expected to see strong growth in the next few years. It will grow to $4.39 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to development of targeted biologics, ai-powered diagnostics, expansion of rare disease centers, telemedicine adoption, growing patient advocacy and awareness. Major trends in the forecast period include early diagnosis adoption, novel biologic therapies, minimally invasive treatment preference, integration of ai in diagnostics, telehealth for rare diseases.

The rising prevalence of autoimmune diseases is expected to drive the growth of the scleroderma diagnostics and therapeutics market in the coming years. Autoimmune diseases occur when the immune system mistakenly attacks the body’s own healthy cells. Their prevalence is increasing due to genetic predisposition, as certain gene variations affect immune system activity and connective tissue function. Scleroderma diagnostics and therapeutics aid in managing autoimmune diseases by enabling early detection and personalized treatment approaches, which streamline clinical decision-making and improve patient outcomes and quality of life. For example, in June 2024, the Australian Institute of Health and Welfare reported that 514,000 (2%) people in Australia were living with rheumatoid arthritis in 2022, representing 2% of the total disease burden and 16% of the burden of musculoskeletal conditions in 2023, with 1,322 deaths (5.1 deaths per 100,000 population) recorded in 2022, accounting for 0.7% of all deaths. Thus, the growing prevalence of autoimmune diseases is driving the expansion of the scleroderma diagnostics and therapeutics market.

Major players in the scleroderma diagnostics and therapeutics market are concentrating on advancements in diagnostic methods, such as fully human CD19 CAR T-cell therapy, to enhance disease management and patient outcomes. Human CD19 CAR T-cell therapy is a type of immunotherapy in which a patient’s T cells (a type of immune cell) are genetically modified to express a chimeric antigen receptor (CAR) that targets CD19, a protein on B cells. For instance, in October 2023, Kyverna Therapeutics Inc., a US-based biopharmaceutical company, obtained FDA clearance for its Investigational New Drug (IND) application for KYV-101, a fully human CD19 CAR T-cell therapy, to begin a Phase 1/2 clinical trial for diffuse cutaneous systemic sclerosis (scleroderma). The upcoming KYSA-5 trial will evaluate the safety and efficacy of KYV-101, which targets B cells involved in autoimmune disease progression. This therapy is intended to reset the immune system and improve outcomes for scleroderma patients.

In October 2023, Amgen Inc., a US-based biotechnology firm, acquired Horizon Therapeutics plc for $27.8 billion. Through this acquisition, Amgen seeks to enhance its rare autoimmune and inflammatory disease portfolio by leveraging Horizon Therapeutics’ expertise and innovative drug pipeline. Horizon Therapeutics plc, based in Ireland, focuses on developing treatments for scleroderma, particularly through novel therapies targeting fibrosis and immune system regulation.

Major companies operating in the scleroderma diagnostics and therapeutics market are Johnson and Johnson, F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Bayer AG, Sanofi S.A., GSK plc, Boehringer Ingelheim International GmbH, Galapagos NV, Inventiva S.A., Redx Pharma plc, Kadmon Holdings Inc., Certa Therapeutics Pty Ltd, Corbus Pharmaceuticals Holdings Inc., aTyr Pharma Inc., MediciNova Inc., Pfizer Inc., Novartis AG, Abbvie Inc., Bristol Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Amgen Inc., UCB Pharma, CSL Behring, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical Co. Ltd., Kyowa Kirin.

North America was the largest region in the scleroderma diagnostics and therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the scleroderma diagnostics and therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the scleroderma diagnostics and therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the scleroderma diagnostics and therapeutics market by increasing costs of imported diagnostic equipment, biologics, and specialized reagents. The rise in production and procurement expenses has impacted the early-stage diagnostic devices and therapeutic biologics segments, particularly in North America and Europe. Some companies are benefiting by investing in local manufacturing and sourcing alternatives, which enhances domestic capabilities and encourages innovation in cost-efficient therapies.

The scleroderma diagnostics and therapeutics market research report is one of a series of new reports that provides scleroderma diagnostics and therapeutics market statistics, including scleroderma diagnostics and therapeutics industry global market size, regional shares, competitors with a scleroderma diagnostics and therapeutics market share, detailed scleroderma diagnostics and therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the scleroderma diagnostics and therapeutics industry. This scleroderma diagnostics and therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Scleroderma diagnostics and therapeutics encompass advanced testing techniques and targeted treatments aimed at detecting and managing scleroderma, a chronic autoimmune disorder marked by the hardening and tightening of the skin and connective tissues. These approaches assist in identifying symptoms such as Raynaud’s phenomenon, skin thickening, and involvement of internal organs.

The primary drug categories for scleroderma diagnostics and therapeutics include corticosteroids, immunosuppressive agents, endothelin receptor antagonists, calcium channel blockers, phosphodiesterase type 5 (PDE-5) inhibitors, chelating agents, prostacyclin analogues, and others. Corticosteroids are steroid hormones that help decrease inflammation and modulate the immune system. The diagnostic methods comprise blood tests, imaging techniques, skin biopsy, pulmonary function tests, electrocardiograms, and echocardiograms, and are categorized into systemic scleroderma and localized scleroderma based on their use. These therapies can be administered via oral, injectable, and topical routes, catering to various end-users including hospitals, diagnostic centers, private laboratories, government laboratories, and more.

The scleroderma diagnostics and therapeutics market includes revenues earned by entities by providing services such as advanced diagnostic imaging and laboratory testing, biomarker and genetic testing, targeted therapeutic development, personalized treatment planning, and remote patient monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.